파이오제약 (PHIO) 주가

파이오제약(PHIO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.09 (+0.00%), 시가총액 $0.01B, 52주 범위 $0.86 ~ $2.96.

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

핵심 지표

• 현재가: $1.09 (+0.00%)
• 시가총액: $0.01B
• 52주 최저~최고: $0.86 ~ $2.96
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

파이오제약의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

파이오제약 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.62
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문